Physician profile
Kevin E Hohl
NPI 1912902362
$2,276.25
in general payments reported to CMS, 2019-2025
27 companies · $631 in 2025
The $631 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $944 · 2020: $191 · 2022: $18.08 · 2023: $229 · 2024: $263 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $244.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $216.25 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $197.36 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Pfizer INC. | $187.02 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $166.90 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $158.28 | 2019-2025 | Shingrix, Arexvy |
| Dexcom, INC. | $126.71 | 2019-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $104.13 | 2019-2025 | |
| Medtronic, INC. | $98.45 | 2023-2025 | Closurefast, Minimed 780g |
| Lilly USA, LLC | $96.46 | 2019-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $79.93 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Tactile Systems Technology INC | $69.13 | 2019-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $61.02 | 2019 | |
| Concordia Pharmaceuticals INC. | $53.14 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $50.82 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $48.77 | 2019-2020 | |
| Valeritas, INC. | $46.83 | 2019 | |
| Seqirus USA INC | $36.51 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Sanofi Pasteur INC. | $31.63 | 2019-2023 | |
| Globus Medical, INC. | $28.24 | 2025 | Senza |
| Teva Pharmaceuticals USA, INC. | $27.59 | 2020 | |
| Abbott Laboratories | $20.53 | 2024 | Freestyle Libre 3 |
| Allergan, INC. | $17.89 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.74 | 2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.44 | 2019 | |
| Amarin Pharma, INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Hohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.